Marcoms group Creston has issued an interim statement for the third quarter, reporting group revenue up just 1% year-on-year, resulting it says from a combination of client budget cuts and project delays within its UK health business
Marcoms group Creston has issued an interim statement for the third quarter, reporting group revenue up just 1% year-on-year, resulting it says from a combination of client budget cuts and project delays within its UK health business
The changes within the pharmaceutical industry show no signs of abating as financial pressures – whether from the decline of the traditional blockbuster or the rise of cost-containment measures – press down on companies.